1. Home
  2. BNTC vs QTTB Comparison

BNTC vs QTTB Comparison

Compare BNTC & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Benitec Biopharma Inc.

BNTC

Benitec Biopharma Inc.

HOLD

Current Price

$13.68

Market Cap

454.2M

Sector

Health Care

ML Signal

HOLD

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

HOLD

Current Price

$16.03

Market Cap

450.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNTC
QTTB
Founded
1995
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
454.2M
450.1M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
BNTC
QTTB
Price
$13.68
$16.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$27.67
$13.00
AVG Volume (30 Days)
162.0K
420.5K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
80.94
136.78
EPS
N/A
N/A
Revenue
N/A
$53,737,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.85
$1.62
52 Week High
$16.76
$23.57

Technical Indicators

Market Signals
Indicator
BNTC
QTTB
Relative Strength Index (RSI) 60.62 55.09
Support Level $11.28 $14.44
Resistance Level $13.79 $16.78
Average True Range (ATR) 0.83 0.88
MACD 0.07 -0.08
Stochastic Oscillator 89.02 55.33

Price Performance

Historical Comparison
BNTC
QTTB

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

Share on Social Networks: